Tevogen Bio Holdings (TVGN) AI Stock Analysis

• Market Cap: $76.75M
• Dividend Yield: N/A
• Average Volume (3M): 557.82K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: N/A
• EPS Growth: -234.46%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 198,689,930
• 10 Day Avg. Volume: 531,944
• 30 Day Avg. Volume: 557,817
• PEG Ratio: >-0.01
• Price to Book (P/B): -22.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.59
• Enterprise Value/Market Cap: 2.03
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -140.78
• Enterprise Value/Ebitda: -2.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.33 ▼(-4.57% Downside)

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, negative equity, and continued cash burn). Technicals also weigh on the rating due to a clear downtrend across key moving averages with negative MACD. Valuation is difficult to support with a negative P/E and no dividend yield provided.

Positive Factors

Platform Expansion

Expanding the ExacTcell platform to cover more HLA types increases the potential patient base, enhancing long-term market reach and therapeutic impact.

Strategic Partnerships

Collaborations with tech giants like Microsoft and Databricks enhance Tevogen's R&D capabilities, improving efficiency and scalability in drug development.

Product Pipeline Potential

A strong revenue forecast for TVGN 116 indicates promising market potential and supports the viability of Tevogen's innovative drug development model.

Negative Factors

Financial Performance

Persistent financial losses and lack of revenue generation indicate ongoing financial instability, posing risks to long-term sustainability and growth.

Balance Sheet Weakness

Negative equity and limited assets restrict financial flexibility and increase solvency risk, challenging the company's ability to fund future operations.

Cash Flow Challenges

Ongoing negative cash flow highlights cash burn issues, limiting the company's capacity to invest in growth and innovation without external funding.

Tevogen Bio Holdings Business Overview & Revenue Model

Company Description

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

How the Company Makes Money

Tevogen Bio Holdings generates revenue primarily through the development and commercialization of its proprietary immunotherapy products. The company's revenue model includes income from product sales, licensing agreements, and strategic partnerships with pharmaceutical companies and research institutions. Additionally, Tevogen Bio may receive funding through grants and collaborations aimed at advancing its research initiatives. As the company progresses through clinical trials and secures regulatory approvals, sales of approved therapies are expected to be a significant revenue stream. Strategic alliances and partnerships also play a crucial role in expanding market reach and driving earnings.

Tevogen Bio Holdings Financial Statement Overview

Summary

Tevogen Bio Holdings is facing significant financial challenges with consistent operational losses, high leverage due to negative equity, and negative cash flow from operations. These factors suggest substantial financial risks, which are common in the biotech industry during early development stages.

Income Statement

Tevogen Bio Holdings has shown consistent negative EBIT and net income over the years with no revenue reported. The lack of revenue growth and recurring losses highlight challenges in achieving profitability. This is typical for biotechnology firms in the development phase but poses a risk to financial stability.

Balance Sheet

The company exhibits a high debt-to-equity ratio due to negative equity, reflecting high leverage and potential financial instability. Total assets have decreased significantly, and equity is negative, indicating financial distress. The negative equity also reflects accumulated losses over time.

Cash Flow

Tevogen's cash flow statement reveals negative operating and free cash flows, indicating cash burn typical of early-stage biotech companies. However, financing activities provided positive cash flow, suggesting reliance on external funding for operations. The absence of positive cash flow from operations poses sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.11M	-403.58K	-378.36K	0.00	0.00
EBITDA	-72.02M	-13.14M	-58.89M	4.41M	-14.99M
Net Income	-73.15M	-10.11M	-60.48M	4.41M	-15.60M
Balance Sheet
Total Assets	4.49M	3.46M	5.51M	7.74M	7.66M
Cash, Cash Equivalents and Short-Term Investments	1.04M	1.28M	1.05M	5.48M	7.12M
Total Debt	7.53M	2.89M	95.42M	40.01M	23.48M
Total Liabilities	12.32M	10.14M	99.93M	41.69M	24.15M
Stockholders Equity	-7.82M	-6.67M	-94.43M	-33.95M	-16.49M
Cash Flow
Free Cash Flow	-33.69M	-12.00M	-8.30M	-9.13M	-5.38M
Operating Cash Flow	-33.69M	-12.00M	-8.17M	-8.66M	-5.27M
Investing Cash Flow	0.00	0.00	-133.00K	-479.04K	-109.73K
Financing Cash Flow	31.81M	12.23M	3.87M	7.50M	12.50M

Tevogen Bio Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Neutral. The current price of 0.35 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.44, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.50 is Neutral, neither overbought nor oversold. The STOCH value of 74.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVGN.

Tevogen Bio Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCCC	56 Neutral	$215.15M	-1.31	-59.98%	―	-10.57%	1.98%
NVCT	54 Neutral	$225.15M	-6.71	-158.88%	―	―	-16.26%
STTK	53 Neutral	$303.74M	-4.55	-57.84%	―	-84.46%	33.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	48 Neutral	$146.32M	-1.52	-26.69%	―	―	25.84%
TVGN	42 Neutral	$76.75M	-2.20	―	―	―	-234.46%